Based on collective data, NUCB2/nesfatin-1 with its associated regulatory processes are recognized as promising targets for treating type 2 diabetes, obesity and metabolic syndrome (Nakata and Yada, 2013). Here, NUCB2 is linked to metabolic syndrome.